Ethics and Clinical Neuroinnovation

New ways of understanding the brain - its nature, its capacities, its function, and its dysfunction - hold great promise for human wellbeing. Novel therapeutics spurred by this understanding have important roles addressing many clinical conditions, including Alzheimer Disease, depression, addiction, and obsessive-compulsive disorder. This unique title explores a wide range of groundbreaking sciences and clinical practices for brain-based conditions, including deep brain stimulation, optogenetics, technology-delivered therapies, predictive testing, and new clinical uses of ketamine, cannabis, and other psychoactive substances. An introduction to theimperative to develop new treatmentsfor devastating brain disordersand the state of current therapeutics in psychiatry, addiction, and behavioral disorders is presented, and chapters from leading physician-scientists andneuroethicists outline the clinical and theethical issues arising in innovation and in the creation of new therapeutics for brain diseases. Written by renowned thought leaders in their fields, the book presents tightly writtencontributions on novel qualitative and quantitativedata fromstakeholders in the field, includingneuroscientist-clinicians,people living with mental illness and/or addictions, and oversight/policy stakeholders. Concise, anticipatory,andcentered on the principles governing human biomedical research and innovation in developing novel therapeutics for brain disorders, Ethics and Clinical Neuroinnovation will be of great value to clinicians, researchers, and students from a vast array of backgrounds, including neuroethics, neuroscience, psychology, psychiatry, philosophy, entrepreneurship, and the law.